Supplementary table: Comparison between FeNONOS and FeNONOV in patients treated with ICS or ICS/LABA and those without ICS therapy

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ICS or ICS/LABA | n | FeNONOV, ppb | FeNONOS, ppb | Difference in FeNONOS and FeNONOV, ppb | *P* |
| **No** | 21 | 87.0(57.5,115.0) | 116.0(90.5,162.5) | 27.0(19.0, 54.0) | <0.001 |
| **Yes** | 36 | 58.5(31.5, 89.8) | 73.5(38.8, 119.3) | 17.0(8.8, 33.5) | <0.001 |

\*A total of 57 patients were analyzed in the table (50 cases were excluded for under treatment of systemic corticosteroids or LTRA or Omalizumab to avoid interference). Comparisons between FeNONOS and FeNONOV in subgroups were tested by the related-samples nonparametric Wilcoxon rank-sum test.